Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Diagnosis and Treatment Approach for Oligo-Recurrent and Oligo-Progressive Renal Cell Carcinoma.
Bekku K, Kawada T, Sekito T, Yoshinaga K, Maruyama Y, Yamanoi T, Tominaga Y, Sadahira T, Katayama S, Iwata T, Nishimura S, Edamura K, Kobayashi T, Kobayashi Y, Araki M, Niibe Y. Bekku K, et al. Among authors: maruyama y. Cancers (Basel). 2023 Dec 17;15(24):5873. doi: 10.3390/cancers15245873. Cancers (Basel). 2023. PMID: 38136417 Free PMC article. Review.
Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.
Sadahira T, Wada K, Araki M, Ishii A, Takamoto A, Kobayashi Y, Watanabe M, Watanabe T, Nasu Y, Kumon H; Okayama Urological Research Group (OURG). Sadahira T, et al. J Antimicrob Chemother. 2017 Feb;72(2):529-534. doi: 10.1093/jac/dkw424. Epub 2016 Oct 12. J Antimicrob Chemother. 2017. PMID: 27733519 Free article. Clinical Trial.
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S, Iwata T, Kawada T, Okamoto Y, Sano Y, Kawago Y, Miyake S, Moriwake T, Kuinose A, Horikawa Y, Tsuboi K, Tsuboi I, Sakaeda K, Nakatsuka H, Takamoto A, Hirata T, Shirasaki Y, Yamasaki T, Morinaka H, Nagasaki N, Hara T, Ochi A, Okumura M, Watanabe T, Sekito T, Kawano K, Horii S, Yamanoi T, Nagao K, Yoshinaga K, Maruyama Y, Tominaga Y, Sadahira T, Nishimura S, Edamura K, Kobayashi T, Kusumi N, Kurose K, Yamamoto Y, Sugimoto M, Nakada T, Sasaki K, Takenaka T, Ebara S, Miyaji Y, Wada K, Kobayashi Y, Araki M. Katayama S, et al. Among authors: maruyama y. Urol Oncol. 2024 Mar;42(3):70.e11-70.e18. doi: 10.1016/j.urolonc.2023.11.009. Epub 2023 Dec 20. Urol Oncol. 2024. PMID: 38129282
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
Sekito T, Bekku K, Katayama S, Watanabe T, Tsuboi I, Yoshinaga K, Maruyama Y, Yamanoi T, Kawada T, Tominaga Y, Sadahira T, Iwata T, Nishimura S, Kusumi N, Edamura K, Kobayashi T, Kurose K, Ichikawa T, Miyaji Y, Wada K, Kobayashi Y, Araki M. Sekito T, et al. Among authors: maruyama y. Clin Genitourin Cancer. 2024 Aug;22(4):102097. doi: 10.1016/j.clgc.2024.102097. Epub 2024 Apr 17. Clin Genitourin Cancer. 2024. PMID: 38763123
Propensity score-matched analysis comparing robot-assisted partial nephrectomy and image-guided percutaneous cryoablation for cT1 renal cell carcinoma.
Yamanoi T, Bekku K, Yoshinaga K, Maruyama Y, Nagao K, Kawada T, Tominaga Y, Umakoshi N, Sadahira T, Katayama S, Iwata T, Uka M, Nishimura S, Edamura K, Kobayashi T, Kobayashi Y, Hiraki T, Araki M. Yamanoi T, et al. Among authors: maruyama y. Urol Oncol. 2024 Dec;42(12):453.e15-453.e22. doi: 10.1016/j.urolonc.2024.09.012. Epub 2024 Oct 5. Urol Oncol. 2024. PMID: 39368943
Significance of Targeted Antimicrobial Prophylaxis Using Rectal-culture Selective Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial.
Sadahira T, Sekito T, Maruyama Y, Ichikawa T, Kurihara Y, Shiraishi H, Sakuma T, Tokunaga M, Mitsui Y, Kusumi N, Tominaga Y, Katayama S, Iwata T, Nishimura S, Edamura K, Kobayashi T, Watanabe M, Hiyama Y, Yamada H, Kurata H, Kondo T, Mitsui M, Takenaka T, Kiyota H, Araki M, Miyazaki J, Takahashi S, Yamamoto S, Wada K. Sadahira T, et al. Among authors: maruyama y. Urology. 2024 Dec 16:S0090-4295(24)01144-0. doi: 10.1016/j.urology.2024.12.018. Online ahead of print. Urology. 2024. PMID: 39694101
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H; SUPPORT Trial Investigators; SUPPORT Trial Investigators. Sakata Y, et al. Among authors: maruyama y. Eur Heart J. 2015 Apr 14;36(15):915-23. doi: 10.1093/eurheartj/ehu504. Epub 2015 Jan 30. Eur Heart J. 2015. PMID: 25637937 Free PMC article. Clinical Trial.
Birth weight and head circumference for 22-29 weeks gestation neonates from an international cohort.
Fenton TR, Alshaikh B, Kusuda S, Helenius K, Modi N, Norman M, Lui K, Lehtonen L, Battin M, Klinger G, Vento M, Lastrucci V, Gagliardi L, Adams M, Marba STM, Isayama T, Hakansson S, Bassler D, Shah PS; International Network for Evaluation of Outcomes (iNeo) of Neonates Investigators. Fenton TR, et al. Arch Dis Child Fetal Neonatal Ed. 2025 Jan 6:fetalneonatal-2024-327845. doi: 10.1136/archdischild-2024-327845. Online ahead of print. Arch Dis Child Fetal Neonatal Ed. 2025. PMID: 39762001
2,419 results